Literature DB >> 19649148

Current concepts of metastasis in melanoma.

Blazej Zbytek1, J Andrew Carlson, Jacqueline Granese, Jeffrey Ross, Martin C Mihm, Andrzej Slominski.   

Abstract

The main cause of death in melanoma patients is widespread metastases. Staging of melanoma is based on the primary tumor thickness, ulceration, lymph node and distant metastases. Metastases develop in regional lymph nodes, as satellite or in-transit lesions, or in distant organs. Lymph flow and chemotaxis is responsible for the homing of melanoma cells to different sites. Standard pathologic evaluation of sentinel lymph nodes fails to find occult melanoma in a significant proportion of cases. Detection of small numbers of malignant melanoma cells in these and other sites, such as adjacent to the primary site, bone marrow or the systemic circulation, may be enhanced by immunohistochemistry, reverse transcription PCR, evaluation of lymphatic vessel invasion and proteomics. In the organs to which melanoma cells metastasize, extravasation of melanoma cells is regulated by adhesion molecules, matrix metalloproteases, chemokines and growth factors. Melanoma cells may travel along external vessel lattices. After settling in the metastatic sites, melanoma cells develop mechanisms that protect them against the attack of the immune system. It is thought that one of the reasons why melanoma cells are especially resistant to killing is the fact that melanocytes (cells from which melanoma cells derive) are resistant to such noxious factors as ultraviolet light and reactive oxygen species. Targeted melanoma therapies are, so far, largely unsuccessful, and new ones, such as adjuvant inhibition of melanogenesis, are under development.

Entities:  

Year:  2008        PMID: 19649148      PMCID: PMC2601641          DOI: 10.1586/17469872.3.5.569

Source DB:  PubMed          Journal:  Expert Rev Dermatol        ISSN: 1746-9872


  160 in total

Review 1.  Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation.

Authors:  Pipsa Saharinen; Tuomas Tammela; Marika J Karkkainen; Kari Alitalo
Journal:  Trends Immunol       Date:  2004-07       Impact factor: 16.687

2.  Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.

Authors:  Mikhail Pashenkov; Gerda Goëss; Christine Wagner; Markus Hörmann; Tamara Jandl; Anna Moser; Cedrik M Britten; Josef Smolle; Silvia Koller; Cornelia Mauch; Iliana Tantcheva-Poor; Stephan Grabbe; Carmen Loquai; Stefan Esser; Tom Franckson; Achim Schneeberger; Cäcilia Haarmann; Arthur M Krieg; Georg Stingl; Stephan N Wagner
Journal:  J Clin Oncol       Date:  2006-12-20       Impact factor: 44.544

3.  A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.

Authors:  David E Weng; Paul A Masci; Susan F Radka; T Elise Jackson; Patricia A Weiss; Ram Ganapathi; Paul J Elson; William B Capra; Vann P Parker; Jennifer A Lockridge; J Wayne Cowens; Nassim Usman; Ernest C Borden
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

Review 4.  Neuroendocrinology of the skin.

Authors:  A Slominski; J Wortsman
Journal:  Endocr Rev       Date:  2000-10       Impact factor: 19.871

5.  High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers.

Authors:  Martin Klemke; Tatjana Weschenfelder; Mathias H Konstandin; Yvonne Samstag
Journal:  J Cell Physiol       Date:  2007-08       Impact factor: 6.384

6.  A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin.

Authors:  Andrzej Slominski; Jordan Zjawiony; Jacobo Wortsman; Igor Semak; Jeremy Stewart; Alexander Pisarchik; Trevor Sweatman; Josep Marcos; Chuck Dunbar; Robert C Tuckey
Journal:  Eur J Biochem       Date:  2004-11

7.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

Review 8.  Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.

Authors:  Steven J O'Day; Omid Hamid; Walter J Urba
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

9.  Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF.

Authors:  I Depasquale; W D Thompson
Journal:  Histopathology       Date:  2008-03       Impact factor: 5.087

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  65 in total

Review 1.  The lymphatic vasculature in disease.

Authors:  Kari Alitalo
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

2.  Evaluation of a nanocomposite of PEG-curcumin-gold nanoparticles as a near-infrared photothermal agent: an in vitro and animal model investigation.

Authors:  F Rahimi-Moghaddam; N Azarpira; N Sattarahmady
Journal:  Lasers Med Sci       Date:  2018-05-22       Impact factor: 3.161

3.  Melanomas' fatal attraction to lysophosphatidic acid trails: a new prognostic and therapeutic approach?

Authors:  Andrew J Muinonen-Martin; Robert H Insall
Journal:  Melanoma Manag       Date:  2015-05-18

Review 4.  Endometrial metastasis of primary malignant melanoma of the brain.

Authors:  Jessica Little; Kathleen Braniff
Journal:  BMJ Case Rep       Date:  2018-05-30

5.  A Targeted Proteomic Approach for Heat Shock Proteins Reveals DNAJB4 as a Suppressor for Melanoma Metastasis.

Authors:  Weili Miao; Lin Li; Yinsheng Wang
Journal:  Anal Chem       Date:  2018-05-11       Impact factor: 6.986

6.  A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.

Authors:  Elena Kurenova; Deniz Ucar; Jianqun Liao; Michael Yemma; Priyanka Gogate; Wiam Bshara; Ulas Sunar; Mukund Seshadri; Steven N Hochwald; William G Cance
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Melanoma-derived exosomes induce reprogramming fibroblasts into cancer-associated fibroblasts via Gm26809 delivery.

Authors:  Tairan Hu; Jiacai Hu
Journal:  Cell Cycle       Date:  2019-09-23       Impact factor: 4.534

8.  Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells.

Authors:  Jessica D Hathaway-Schrader; Bently P Doonan; Azim Hossain; Faisal F Y Radwan; Lixia Zhang; Azizul Haque
Journal:  J Cell Biochem       Date:  2017-10-18       Impact factor: 4.429

9.  Potential Use of Transferred Lymph Nodes as Metastasis Detectors after Tumor Excision.

Authors:  Fabio Nicoli; Pedro Ciudad; Seong Yoon Lim; Davide Lazzeri; Christopher D'Ambrosia; Kidakorn Kiranantawat; Ram M Chilgar; Stamatis Sapountzis; Bulent Sacak; Hung-Chi Chen
Journal:  Arch Plast Surg       Date:  2015-07-14

Review 10.  Cytochromes p450 and skin cancer: role of local endocrine pathways.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Igor Semak; Blazej Zbytek; Alexander Pisarchik; Wei Li; Jordan Zjawiony; Robert C Tuckey
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.